Enterprise Value

1.595B

Cash

389M

Avg Qtr Burn

-23.79M

Short % of Float

15.41%

Insider Ownership

1.22%

Institutional Own.

88.38%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Orladeyo (Berotralstat) Details
Rare diseases, Rare genetic disease, Hereditary angioedema

Approved

Quarterly sales

Approved

Quarterly sales

BCX10013 (Oral Factor D inhibitor) Details
Complement mediated diseases, Paroxysmal nocturnal hemoglobinuria

Phase 1

Data readout

BCX9250 (ALK2 inhibitor) Details
Fibrodysplasia ossificans progressiva

Failed

Discontinued

Failed

Discontinued

BCX9930 (Oral Factor D inhibitor) Details
Paroxysmal nocturnal hemoglobinuria

Failed

Discontinued